VISHAY INTERTECHNOLOGY INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VISHAY INTERTECHNOLOGY INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.07B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.94B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.40B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.50B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.24B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $2.50B | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $609.58M | Feb 14, 2020 |
| FY2019 | Sep 28, 2019 | $628.33M | Feb 14, 2020 |
| FY2019 | Jun 29, 2019 | $685.24M | Feb 14, 2020 |
| FY2019 | Mar 30, 2019 | $745.16M | Feb 14, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $594.88M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $626.29M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $974.49M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.06B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $887.91M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $581.90M | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $135.36M | Feb 14, 2020 |
| FY2019 | Sep 28, 2019 | $150.08M | Feb 14, 2020 |
| FY2019 | Jun 29, 2019 | $174.60M | Feb 14, 2020 |
| FY2019 | Mar 30, 2019 | $211.16M | Feb 14, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.98M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($31.15M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $323.82M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $428.81M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $297.97M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $122.92M | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $13.96M | Feb 14, 2020 |
| FY2019 | Sep 28, 2019 | $30.04M | Feb 14, 2020 |
| FY2019 | Jun 29, 2019 | $44.48M | Feb 14, 2020 |
| FY2019 | Mar 30, 2019 | $75.46M | Feb 14, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.87M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.63M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $486.14M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $615.49M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $467.80M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $209.71M | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $24.18M | Feb 14, 2020 |
| FY2019 | Sep 28, 2019 | $51.03M | Feb 14, 2020 |
| FY2019 | Jun 29, 2019 | $79.49M | Feb 14, 2020 |
| FY2019 | Mar 30, 2019 | $107.74M | Feb 14, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.39M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $120.13M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $99.51M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $81.18M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $77.38M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $70.86M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $69.83M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $72.89M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $67.15M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $66.84M | Feb 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $538.02M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $513.56M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $488.35M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $443.50M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $420.11M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $371.45M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $384.63M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $403.40M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $367.83M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $356.01M | Feb 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.31M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $173.70M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $365.70M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $484.29M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $457.10M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $314.94M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $296.44M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $258.51M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $368.78M | Feb 14, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.23B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.11B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $4.24B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.87B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.54B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $3.15B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $3.12B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $3.11B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $3.46B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $3.08B | Feb 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.08B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.04B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.82B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.80B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.58B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.63B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.72B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.78B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.42B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.03B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.20B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.05B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.74B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.58B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $1.49B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.38B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.43B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.57B | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.39M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $179.01M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $201.42M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $201.43M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $165.27M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $158.18M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $150.64M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $147.48M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $142.74M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $141.41M | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $892.23M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $955.50M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $773.23M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $401.69M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $138.99M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $72.18M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($61.26M) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($362.25M) | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | ($307.42M) | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $514.97M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $590.29M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $972.72M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $610.83M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $774.11M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $619.87M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $694.13M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $686.03M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $748.03M | Feb 15, 2019 |
| FY2018 | Dec 31, 2016 | $471.78M | Feb 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $950.89M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $905.02M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $818.19M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $500.94M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $455.67M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $394.89M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $499.15M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $494.51M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $370.47M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $357.02M | Feb 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 14, 2020 |
| FY2019 | Sep 28, 2019 | 0 | Feb 14, 2020 |
| FY2019 | Jun 29, 2019 | 0 | Feb 14, 2020 |
| FY2019 | Mar 30, 2019 | 0 | Feb 14, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 14, 2020 |
| FY2019 | Sep 28, 2019 | 0 | Feb 14, 2020 |
| FY2019 | Jun 29, 2019 | 0 | Feb 14, 2020 |
| FY2019 | Mar 30, 2019 | 0 | Feb 14, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | 150.61M | Feb 25, 2011 |
| FY2010 | Dec 31, 2009 | 172.28M | Feb 25, 2011 |